not address specific targets to be recommended or used. There have been 2 international meetings to discuss potential targets: the use of either disease activity (MDA) or disease activity in psoriatic arthritis (DAPSA) The ACR/NPF PsA guideline conditionally recommends a TNFi biologic over an OSM agent in patients with active PsA. The Strong recommendation supported by moderate-quality evidence, rated down for indirectness. * Active psoriatic arthritis (PsA) is defined as disease causing